Cargando…
The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders
Background: Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics and tic-specific behavioral therapies. However, due to a lack of trained therapists and adverse events of antipsychotic medi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725747/ https://www.ncbi.nlm.nih.gov/pubmed/33324255 http://dx.doi.org/10.3389/fpsyt.2020.575826 |
_version_ | 1783620764919922688 |
---|---|
author | Jakubovski, Ewgeni Pisarenko, Anna Fremer, Carolin Haas, Martina May, Marcus Schumacher, Carsten Schindler, Christoph Häckl, Sebastian Aguirre Davila, Lukas Koch, Armin Brunnauer, Alexander Cimpianu, Camelia Lucia Lutz, Beat Bindila, Laura Müller-Vahl, Kirsten |
author_facet | Jakubovski, Ewgeni Pisarenko, Anna Fremer, Carolin Haas, Martina May, Marcus Schumacher, Carsten Schindler, Christoph Häckl, Sebastian Aguirre Davila, Lukas Koch, Armin Brunnauer, Alexander Cimpianu, Camelia Lucia Lutz, Beat Bindila, Laura Müller-Vahl, Kirsten |
author_sort | Jakubovski, Ewgeni |
collection | PubMed |
description | Background: Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics and tic-specific behavioral therapies. However, due to a lack of trained therapists and adverse events of antipsychotic medication many patients seek alternative treatment options including cannabis. Based on the favorable results obtained from case studies on different cannabis-based medicines as well as two small randomized controlled trials using delta-9-tetrahydrocannabinol (THC), we hypothesize that the cannabis extract nabiximols can be regarded as a promising new and safe treatment strategy in TS. Objective: To test in a double blind randomized clinical trial, whether treatment with the cannabis extract nabiximols is superior to placebo in patients with chronic tic disorders. Patients and Methods: This is a multicenter, randomized, double-blind, placebo controlled, parallel-group, phase IIIb trial, which aims to enroll 96 adult patients with chronic tic disorders (TS or chronic motor tic disorder) across 6 centers throughout Germany. Patients will be randomized with a 2:1 ratio into a nabiximols and a placebo arm. The primary efficacy endpoint is defined as tic reduction of at least 30% (compared to baseline) according to the Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) after 13 weeks of treatment. In addition, several secondary endpoints will be assessed including changes in different psychiatric comorbidities, quality of life, driving ability, and safety assessments. Discussion: This will be the first large, controlled study investigating efficacy and safety of a cannabis-based medicine in patients with TS. Based on available data using different cannabis-based medicines, we expect not only a reduction of tics, but also an improvement of psychiatric comorbidities. If the cannabis extract nabiximols is proven to be safe and effective, it will be a valuable alternative treatment option. The results of this study will be of high health-economic relevance, because a substantial number of patients uses cannabis (illegally) as self-medication. Conclusion: The CANNA-TICS trial will clarify whether nabiximols is efficacious and safe in the treatment of patients with chronic tic disorders. Clinical Trial Registration: This trial is registered at clinicaltrialsregister.eu (Eudra-CT 2016-000564-42) and clinicaltrials.gov (NCT03087201). |
format | Online Article Text |
id | pubmed-7725747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77257472020-12-14 The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Jakubovski, Ewgeni Pisarenko, Anna Fremer, Carolin Haas, Martina May, Marcus Schumacher, Carsten Schindler, Christoph Häckl, Sebastian Aguirre Davila, Lukas Koch, Armin Brunnauer, Alexander Cimpianu, Camelia Lucia Lutz, Beat Bindila, Laura Müller-Vahl, Kirsten Front Psychiatry Psychiatry Background: Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics and tic-specific behavioral therapies. However, due to a lack of trained therapists and adverse events of antipsychotic medication many patients seek alternative treatment options including cannabis. Based on the favorable results obtained from case studies on different cannabis-based medicines as well as two small randomized controlled trials using delta-9-tetrahydrocannabinol (THC), we hypothesize that the cannabis extract nabiximols can be regarded as a promising new and safe treatment strategy in TS. Objective: To test in a double blind randomized clinical trial, whether treatment with the cannabis extract nabiximols is superior to placebo in patients with chronic tic disorders. Patients and Methods: This is a multicenter, randomized, double-blind, placebo controlled, parallel-group, phase IIIb trial, which aims to enroll 96 adult patients with chronic tic disorders (TS or chronic motor tic disorder) across 6 centers throughout Germany. Patients will be randomized with a 2:1 ratio into a nabiximols and a placebo arm. The primary efficacy endpoint is defined as tic reduction of at least 30% (compared to baseline) according to the Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) after 13 weeks of treatment. In addition, several secondary endpoints will be assessed including changes in different psychiatric comorbidities, quality of life, driving ability, and safety assessments. Discussion: This will be the first large, controlled study investigating efficacy and safety of a cannabis-based medicine in patients with TS. Based on available data using different cannabis-based medicines, we expect not only a reduction of tics, but also an improvement of psychiatric comorbidities. If the cannabis extract nabiximols is proven to be safe and effective, it will be a valuable alternative treatment option. The results of this study will be of high health-economic relevance, because a substantial number of patients uses cannabis (illegally) as self-medication. Conclusion: The CANNA-TICS trial will clarify whether nabiximols is efficacious and safe in the treatment of patients with chronic tic disorders. Clinical Trial Registration: This trial is registered at clinicaltrialsregister.eu (Eudra-CT 2016-000564-42) and clinicaltrials.gov (NCT03087201). Frontiers Media S.A. 2020-11-26 /pmc/articles/PMC7725747/ /pubmed/33324255 http://dx.doi.org/10.3389/fpsyt.2020.575826 Text en Copyright © 2020 Jakubovski, Pisarenko, Fremer, Haas, May, Schumacher, Schindler, Häckl, Aguirre Davila, Koch, Brunnauer, Cimpianu, Lutz, Bindila and Müller-Vahl. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Jakubovski, Ewgeni Pisarenko, Anna Fremer, Carolin Haas, Martina May, Marcus Schumacher, Carsten Schindler, Christoph Häckl, Sebastian Aguirre Davila, Lukas Koch, Armin Brunnauer, Alexander Cimpianu, Camelia Lucia Lutz, Beat Bindila, Laura Müller-Vahl, Kirsten The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders |
title | The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders |
title_full | The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders |
title_fullStr | The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders |
title_full_unstemmed | The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders |
title_short | The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders |
title_sort | canna-tics study protocol: a randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725747/ https://www.ncbi.nlm.nih.gov/pubmed/33324255 http://dx.doi.org/10.3389/fpsyt.2020.575826 |
work_keys_str_mv | AT jakubovskiewgeni thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT pisarenkoanna thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT fremercarolin thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT haasmartina thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT maymarcus thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT schumachercarsten thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT schindlerchristoph thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT hacklsebastian thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT aguirredavilalukas thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT kocharmin thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT brunnaueralexander thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT cimpianucamelialucia thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT lutzbeat thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT bindilalaura thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT mullervahlkirsten thecannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT jakubovskiewgeni cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT pisarenkoanna cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT fremercarolin cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT haasmartina cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT maymarcus cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT schumachercarsten cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT schindlerchristoph cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT hacklsebastian cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT aguirredavilalukas cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT kocharmin cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT brunnaueralexander cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT cimpianucamelialucia cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT lutzbeat cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT bindilalaura cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders AT mullervahlkirsten cannaticsstudyprotocolarandomizedmulticenterdoubleblindplacebocontrolledtrialtodemonstratetheefficacyandsafetyofnabiximolsinthetreatmentofadultswithchronicticdisorders |